BioCentury | Mar 11, 2013
Company News

Alzheimer's Drug Discovery Foundation, Beyond Batten Disease Foundation (BBDF), Harvard, National Multiple Sclerosis Society (NMSS) neurology news

...Led by the university's NeuroDiscovery Center's Laboratory in Drug Discovery in Neurodegeneration (LDDN), the parties established...
BioCentury | Aug 27, 2012
Company News

Beijing Tide Pharmaceutical, NeuroDiscovery, Sosei deal

...NSL-043 ). The undisclosed small molecule has completed two Phase I trials for neuropathic pain. NeuroDiscovery...
...disclose financial details. In 2010, Sosei and NeuroDiscovery terminated a co-development deal for SD118 after NeuroDiscovery...
...save cash. As part of the termination, Sosei gained full ownership of the program and NeuroDiscovery...
BioCentury | Nov 24, 2008
Clinical News

NeuroDiscovery, Sosei preclinical data

...at the Society for Neuroscience meeting in Washington. The small molecule is partnered with Sosei. NeuroDiscovery Ltd....
BioCentury | Jul 28, 2008
Clinical News

SD118: Phase I data

...hypoaesthesia in the 9 patients receiving the 2,000 mg dose. NSL-043 is partnered with Sosei. NeuroDiscovery Ltd....
BioCentury | Apr 14, 2008
Clinical News

SD118: Phase I data

...mg of NSL-043 were well tolerated and showed linear pharmacokinetics. NSL-043 is partnered with Sosei. NeuroDiscovery Ltd....
BioCentury | Jan 14, 2008
Company News

Argenta Discovery, NeuroDiscovery deal

...compound screening service business. Financial terms were not disclosed. Argenta Discovery Ltd. , Harlow, U.K. NeuroDiscovery Ltd....
BioCentury | Jan 14, 2008
Company News

NeuroDiscovery management update

NeuroDiscovery Ltd. (ASX:NDL), Perth, Australia Business: Neurology Hired: Iain Chessell as CEO effective April 8, formerly worldwide head of pain research at GlaxoSmithKline plc WIR Staff...
BioCentury | Dec 3, 2007
Clinical News

NSL-101: Phase II started

...gel after 16 weeks. The company has a worldwide license to NSL-101 from Ampika Ltd. NeuroDiscovery Ltd....
BioCentury | Dec 3, 2007
Clinical News

NSL-101: Phase II started

...placebo after 24 weeks. The company has a worldwide license to NSL-101 from Ampika Ltd. NeuroDiscovery Ltd....
BioCentury | Dec 3, 2007
Clinical News

SD118: Phase I started

...SD118 in 36 healthy male volunteers. The company partnered the compound with Sosei in 2006. NeuroDiscovery Ltd....
Items per page:
1 - 10 of 20
BioCentury | Mar 11, 2013
Company News

Alzheimer's Drug Discovery Foundation, Beyond Batten Disease Foundation (BBDF), Harvard, National Multiple Sclerosis Society (NMSS) neurology news

...Led by the university's NeuroDiscovery Center's Laboratory in Drug Discovery in Neurodegeneration (LDDN), the parties established...
BioCentury | Aug 27, 2012
Company News

Beijing Tide Pharmaceutical, NeuroDiscovery, Sosei deal

...NSL-043 ). The undisclosed small molecule has completed two Phase I trials for neuropathic pain. NeuroDiscovery...
...disclose financial details. In 2010, Sosei and NeuroDiscovery terminated a co-development deal for SD118 after NeuroDiscovery...
...save cash. As part of the termination, Sosei gained full ownership of the program and NeuroDiscovery...
BioCentury | Nov 24, 2008
Clinical News

NeuroDiscovery, Sosei preclinical data

...at the Society for Neuroscience meeting in Washington. The small molecule is partnered with Sosei. NeuroDiscovery Ltd....
BioCentury | Jul 28, 2008
Clinical News

SD118: Phase I data

...hypoaesthesia in the 9 patients receiving the 2,000 mg dose. NSL-043 is partnered with Sosei. NeuroDiscovery Ltd....
BioCentury | Apr 14, 2008
Clinical News

SD118: Phase I data

...mg of NSL-043 were well tolerated and showed linear pharmacokinetics. NSL-043 is partnered with Sosei. NeuroDiscovery Ltd....
BioCentury | Jan 14, 2008
Company News

Argenta Discovery, NeuroDiscovery deal

...compound screening service business. Financial terms were not disclosed. Argenta Discovery Ltd. , Harlow, U.K. NeuroDiscovery Ltd....
BioCentury | Jan 14, 2008
Company News

NeuroDiscovery management update

NeuroDiscovery Ltd. (ASX:NDL), Perth, Australia Business: Neurology Hired: Iain Chessell as CEO effective April 8, formerly worldwide head of pain research at GlaxoSmithKline plc WIR Staff...
BioCentury | Dec 3, 2007
Clinical News

NSL-101: Phase II started

...gel after 16 weeks. The company has a worldwide license to NSL-101 from Ampika Ltd. NeuroDiscovery Ltd....
BioCentury | Dec 3, 2007
Clinical News

NSL-101: Phase II started

...placebo after 24 weeks. The company has a worldwide license to NSL-101 from Ampika Ltd. NeuroDiscovery Ltd....
BioCentury | Dec 3, 2007
Clinical News

SD118: Phase I started

...SD118 in 36 healthy male volunteers. The company partnered the compound with Sosei in 2006. NeuroDiscovery Ltd....
Items per page:
1 - 10 of 20